Piramal Pharma Secures SBTi Approval for Emission Reduction Goals

The Science Based objectives project (SBTi) has formally approved Piramal Pharma Limited, a well-known international pharmaceutical business, for its short-term greenhouse gas emission reduction objectives. This is congruent with Piramal Pharma's fundamental goal of 'Doing Well and Doing Good,' which guides its business strategies and fortifies its resolve to consistently and measurably advance towards a more sustainable future. Within the same timeframe, the company has committed to reducing absolute scope 3 GHG emissions from purchased goods and services, fuel and energy-related activities, upstream transportation and distribution, and the use of sold products by 25%. The company has also committed to reducing absolute scope 1 and 2 GHG emissions by 42% by FY2030 from a base year of FY2022.

Piramal Pharma is now the third international pharmaceutical business in India to be approved by the SBTi. Sustainability, according to Chairperson Nandini Piramal, is at the core of their company strategy, and their continued commitment to lowering GHG emissions and supporting international climate action targets is strengthened by the approval from SBTi.